Q3 Revenue Up 29% to $11.0M, But $5.0M Acquisition Charge Drives $8.9M Net Loss
GRUSF sits 42% above its 52-week low of $0.269 on elevated volume (4.2× avg).
Summary
Revenue rose 29% to $11.0 million from $8.5 million a year ago, with New Jersey up 44% to $4.9 million and gross margin expanding to 49.8%. Adjusted EBITDA climbed 70% to $2.6 million, a 23.3% margin. The GAAP picture is ugly: a net loss of $8.9 million versus $1.6 million of income last year, driven by a $5.0 million loss on the Rogue EBC acquisition after the company chose the existing Dwight facility over building in Waukegan, plus $3.2 million of income tax expense. Cash grew to $16.6 million from $11.5 million at June 30, helped by consolidating the 51%-owned New York subsidiary. Management kept 2026 guidance of $38-$41 million revenue and $7-$9 million Adjusted EBITDA, and 2027 guidance of $55-$63 million and $14-$18 million, both excluding New York, with a revisit planned at Q4 results. The CFO flagged that the New York transaction will complicate the year-end close and audit, and that PCNY's parent may struggle to support back-office integration.
At the time of this announcement, GRUSF was trading at $0.38 on OTC in the Life Sciences sector, with a market capitalization of approximately $95.3M. The 52-week trading range was $0.27 to $0.52. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.